Biocon Ltd and its European partner, Zentiva, have obtained Decentralized Procedure (DCP) approval in the European Union for their generic version of liraglutide, a complex formulation used in the treatment of type 2 diabetes and weight management. This approval paves the way for a more accessible and affordable treatment option for patients across the EU.
The approval specifically covers generic versions of Novo Nordisk's Victoza (liraglutide) for treating type 2 diabetes and Saxenda (liraglutide) for weight management. Type 2 diabetes, characterized by elevated blood glucose levels, affects a significant portion of the global population, with prevalence rising dramatically over the past three decades, according to the World Health Organization (WHO).
The Decentralized Procedure allows for the authorization of medicines in multiple EU member states simultaneously. This is applicable for drugs that do not require centralized authorization and have not already been approved in any member state, according to the European Medicines Agency (EMA).
Liraglutide is a GLP-1 receptor agonist. It mimics the effects of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the body that helps regulate blood sugar levels and appetite. By activating the GLP-1 receptor, liraglutide stimulates insulin release when blood sugar is high, inhibits glucagon secretion, and slows gastric emptying, all of which contribute to improved glycemic control and weight loss.
This approval marks a significant step for Biocon and Zentiva in providing cost-effective alternatives for managing diabetes and obesity, addressing a growing global health concern.
